Lilly Acquires Adverum Biotechnologies for Gene Therapy Advancements

Eli Lilly has acquired Adverum Biotechnologies, a gene therapy company, to expand its genetic medicine capabilities and potentially develop durable vision correction treatments for age-related diseases. Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration. The acquisition signals industry confidence in long-acting intravitreal gene therapy as a path to improved adherence and durable vision correction.